Emtricitabine is an antiviral medicine used to treat HIV infections. It works by stopping the virus from copying itself in the body. It's often taken as a pill, usually once a day.
Every report comes from a Lived member, sent anonymously.
Have you tried Emtricitabine for HIV Infection?
Emtricitabine, sold on its own as Emtriva, is an antiretroviral medicine used to treat HIV-1, the most common type of HIV (human immunodeficiency virus). It is always taken together with other HIV medicines, never by itself, because HIV quickly becomes resistant to a single drug. Emtriva comes as capsules for adults and older children and as a liquid that can be dosed by weight for infants and young children. Most people who take emtricitabine today get it inside a combination pill rather than as Emtriva. Truvada pairs it with tenofovir disoproxil fumarate, another HIV medicine that blocks the same viral enzyme, and Descovy pairs it with a related form, tenofovir alafenamide. Both are used as part of HIV treatment and are also approved for PrEP (pre-exposure prophylaxis), a daily medicine that lowers the chance of getting HIV through sex for people who do not have HIV. Descovy's PrEP approval does not cover people whose risk comes from receptive vaginal sex. Complete one-pill regimens such as Biktarvy also contain emtricitabine. Emtricitabine alone is not used for PrEP, and it is not approved or used on its own to treat hepatitis B.
To multiply, HIV has to copy its genetic material into DNA that it can insert into a person's immune cells. It does this with an enzyme called reverse transcriptase. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI): once inside a cell it is converted into a look-alike of one of the building blocks of DNA. The enzyme picks it up by mistake, and the DNA chain it is building stops short. Blocking this step lowers the amount of virus in the blood, called the viral load, which gives the immune system room to recover. Emtricitabine does not remove HIV that is already hidden in the body, which is why treatment does not cure HIV and needs to continue. Pairing it with drugs that block other steps makes it much harder for the virus to find a way around treatment.
Emtricitabine is taken by mouth once a day, with or without food. For adults, the usual Emtriva dose is one 200 mg capsule. The liquid is absorbed less completely, so the adult liquid dose is 240 mg (24 mL); the two forms should not be swapped milligram for milligram. Children's liquid doses are based on weight, and children who weigh more than 33 kg (about 73 pounds) and can swallow a capsule may take the adult capsule. Combination pills that contain emtricitabine have their own fixed doses. The kidneys clear emtricitabine from the body, so people with reduced kidney function take capsules less often (every second, third or fourth day) or a smaller daily amount of liquid. People on hemodialysis take their dose after dialysis on dialysis days. Taking it at about the same time every day matters more than the exact hour. If a dose is missed, take it when remembered unless the next dose is nearly due; do not double up. Repeated missed doses let the virus multiply and can lead to resistance, which makes HIV harder to treat.
Headache, diarrhea, nausea and rash are the most commonly reported side effects, and in clinical trials they were usually mild to moderate. Some people also notice tiredness, trouble sleeping or unusual dreams, though these are often hard to separate from the other medicines in the regimen. A distinctive effect of emtricitabine is darkening of the skin on the palms or soles. It is usually harmless and painless, and is especially common in children. In the first weeks or months of HIV treatment, a recovering immune system can start reacting to infections that were already present but not causing symptoms, a reaction called immune reconstitution syndrome. New fever, chills, sore throat, cough or other signs of infection after starting treatment should be reported to the prescriber right away. Rarely, medicines in this class cause lactic acidosis (a dangerous buildup of acid in the blood) or severe liver problems. Signs of acid buildup include unusual muscle pain, fast or difficult breathing, extreme weakness or tiredness, and feeling cold in the arms or legs. Signs of liver trouble include yellowing of the skin or eyes, dark urine and pain in the upper right side of the abdomen. Contact the prescriber right away if any of these appear.
Emtricitabine carries an FDA boxed warning about hepatitis B. In people who have both HIV and hepatitis B, stopping emtricitabine can trigger a severe flare of hepatitis B, sometimes leading to liver failure. Everyone is tested for hepatitis B before or when starting it. Anyone with hepatitis B should not stop it, or any pill containing it, without a plan from the prescriber, and will need liver checks for several months afterward. Some people may need a separate hepatitis B medicine. For PrEP with Truvada or Descovy, a negative HIV test is required right before starting and is repeated at least every 3 months. If HIV is present but undetected, PrEP alone is not enough treatment, and the virus can become resistant to these drugs. Symptoms of a new HIV infection, such as fever, tiredness, muscle aches or rash after a possible exposure, should be mentioned before starting or continuing PrEP. Emtricitabine itself has few significant drug interactions, although the other medicines in an HIV regimen often have many. Because it is an ingredient of many combination pills, the prescriber and pharmacist should review the whole regimen, including over-the-counter medicines and supplements, so that the same drug is not taken twice. Pregnancy registry data have not shown an increase in birth defects with emtricitabine, and HIV treatment during pregnancy is important for preventing transmission to the baby. Emtricitabine passes into breast milk. For people taking it to treat HIV, the label advises against breastfeeding because HIV can be passed to the baby, so feeding plans are worth discussing with the HIV care team. For HIV-negative people taking Truvada as PrEP, the benefits of breastfeeding and the need for PrEP can be weighed with the prescriber; breastfeeding is advised against only if a new HIV infection is suspected.
Emtricitabine works as part of a long-term regimen. Blood tests measure the HIV viral load and the CD4 count (a type of immune cell HIV destroys) to show whether treatment is working. The goal is a viral load so low that standard tests cannot detect it, which protects health and greatly lowers the chance of passing HIV to others. Most side effects, if any, are noticeable early and tend to settle. Treatment for HIV continues even when someone feels well, because stopping lets the virus rebound. Kidney function is checked periodically, especially with tenofovir-containing combinations, and people with hepatitis B have liver tests whenever treatment changes. For someone using Truvada or Descovy as PrEP, visits every 3 months include an HIV test and a prescription refill, with kidney tests done periodically.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Emtricitabine, what you've noticed, or ask the community a question.